Audited Financial Results for the quarter and financial year ended March 31, 2026.
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anupam Rasayan India Ltd reported strong FY26 results with standalone revenue from operations at ₹16,756 million, up 87% from ₹8,959 million in FY25. Standalone profit after tax grew 122% to ₹1,614 million versus ₹727 million in the prior year. On a consolidated basis, revenue reached ₹23,655 million (up 65% YoY) with PAT of ₹2,222 million (up 39% YoY). Basic EPS improved to ₹14.32 for standalone and ₹15.09 for consolidated. The Board recommended a final dividend of ₹1.5 per share (15% on ₹10 face value). Key corporate actions include proposed acquisition of up to 74.20% stake in Bliss GVS Pharma Ltd and plans to raise ₹160 crore via NCDs on private placement. The Deputy CFO Mr. Vishal Thakkar resigned. Auditors issued an unmodified (clean) opinion on both standalone and consolidated results.
The company delivered exceptional standalone PAT growth of 122%, far exceeding the 25% threshold, signaling strong operational performance. The upcoming Bliss GVS Pharma acquisition and NCD issuance indicate strategic expansion plans that may require monitoring for dilution or debt impact. The CFO resignation adds minor governance uncertainty.